Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company ...

3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined ...

Earlier this month, Wave Life Sciences reported updated RestorAATion-2 data showing its RNA-editing candidate WVE-006 reduced harmful Z-AAT and restored protective M-AAT to MZ-like levels in alpha-1 ...

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through ...

Strong Buy on WVE-N531 and WVE-006 catalysts, Phase data, and cash runway into 2028. Click for this WVE stock update.

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

Gilead Sciences (GILD) is scheduled to announce Q1 earnings results on Thursday, May 7th, after market close. The consensus EPS Estimate is $1.91 (+5.5% Y/Y), and the consensus revenue estimate is ...

With a net income margin of 31.00% and upside potential of 24.20%, Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best ...

Sydney's life sciences sector has reached a major milestone, with Kurraba Group announcing the first confirmed partners for ION – a purpose-built commercial life sciences precinct set to redefine ...

College of Health Sciences Dean Kristofer Hagglund has transformed the curriculum, location and mission in 13 years as dean.

To help fill the ever-growing need for new health care workers, St. Luke’s University Health Network has just opened its own ...

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform ...